New Leaf Venture Partners

New Leaf Venture Partners is a venture capital company formed in 25 with offices in New York and San Mateo California. The firm currently manages two funds with its most recent fund having closed at $45 million in 27. The firm is looking to make equity investments ranging from $1-$25 million over the lifetime of the investment. The firm looks for companies primarily in the United States and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.
Mike Dybbs
Principal 

PATH

PATH is an international nonprofit global health organization that was founded in 1977 and is headquartered in Seattle with 12+ employees in more than 3 offices around the world. PATH is one of the largest nonprofit organizations in global health today. PATH works on a wide array of emerging and persistent global health issues in the areas of health technologies maternal health child health reproductive health vaccines and immunization and emerging and epidemic diseases such as HIV malaria and tuberculosis. PATH is best known for developing and adapting technologies such as improved vaccination devices and new tools to prevent cervical cancer to address the health needs of developing countries. It targets health problems evaluates possible solutions and assesses whether they would be useful in finding health solutions.
Bill Cadwallader
Senior Commercialization Officer Diagnostics 
Greg Zwisler
Commercialization Officer 

PBM Capital Group

PBM Capital is a hybrid family office and operating company based in Charlottesville Virginia with an additional office in New York City. The firm is funded and led by the successful life science entrepreneur Paul Manning who started and sold several companies in his career. The firm can make investments ranging from approximately $5 to $1 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity controlling interest in-licensing MBO/LBO growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.
Jayson Rieger
SVP of Business Development & Portfolio Management 

Plug and Play Tech Center United States

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

Phillip Vincent
Corporate Partnerships Manager 

Plug and Play Ventures United States

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.  

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.


Neda Amidi
Investment Associate 

River Cities Capital Funds United States

River Cities Capital Fund is a private equity firm founded in 1994 and based in Cincinnati, Ohio. The firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

Rik Vandevenne
Director 

RiverVest Venture Partners United States

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

Year Founded
2000
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Karen Spilizewski
VP 

Safeguard Scientifics

Safeguard Scientifics is a publicly traded capital deployment firm founded in 1953 and is based in Wayne PA. The firm makes deployments from an evergreen fund and is actively seeking new investments in the healthcare sector. Initial equity placements are typically of $5-1m with the potential for a total allocation of $2-25m over the life of an investment. The firm focuses on North America with a concentration in the Mid-Atlantic and San Francisco Bay Area regions. Deployments are made at a range of stages from early-stage to growth expansion and recapitalization. Safeguard Scientifics prefers to be a sizable minority investor.
Gary Kurtzman
Managing Director 

Sand Hill Angels

Sand Hill Angels is an angel group that was founded in 2 and is headquartered in Sunnyvale California. The group focuses on investments in early-stage (from seed to series C) companies in the Life Sciences IT Internet and Clean Tech sectors. The group prefers to make equity and convertible notes investments and the typical investment size ranges from $.1million to $.5million. The group will consider syndicating with other investors for larger investments. The group will consider companies across the US.
Stephen Pollitt
Board Member Membership Chair 

Symbient Product Development United States

Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing

Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.

 

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.

 

Our Portfolio Includes:

  • Diagnostics / Molecular Diagnostics
  • Sample collection / preparation
  • Life Sciences / Microfluidics
  • OTC Consumer products
  • Respiratory
  • Surgical devices and clinical tools
  • Drug Delivery

 

Year Founded
2004
Unique Capabilities

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.
Lisa Coyne
Business Development Manager 
Luke Helm
Director of Business Development